ViiV Healthcare’s Cabenuva beats daily oral ART in Phase IIIb trial

Phase 3positiveCabenuvaPositive

AI Analysis

Summary

ViiV Healthcare's Cabenuva demonstrated superiority over daily oral antiretroviral therapy in a Phase IIIb trial, supporting its use in HIV patients with no resistance to INSTIs or NNRTIs.

Clinical Trial Data

Phase

IIIb

Primary Endpoint

Met

Outcome Details

Cabenuva beat daily oral ART in Phase IIIb trial; data support use in patients with detectable HIV and no resistance to INSTIs or NNRTIs

Importance:6/10

Sentiment:

0.70

HIVPhase_3_DataClinical_TrialPositive_Results

Related Companies

$HR $TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on October 6, 2026 3:13 PM

Read Original